You take a small pill every morning, maybe with coffee, and trust that it is doing its job to keep your blood pressure in a safe range.
For most people, the pill is a quiet background routine they rarely think about.
That routine is now worth a closer look.
Macleods Pharma USA is recalling 3,744 bottles of a three-in-one blood pressure tablet, according to Medical Daily. Lab tests showed the pills do not break down in the body the way they should.
Also read: The colors on your plate may line up with a 7 percent lower risk of early death
The recall covers tablets of olmesartan medoxomil, amlodipine and hydrochlorothiazide at the 40/10/12.5 mg strength.
That combination is often prescribed when one drug alone is not enough to control blood pressure.
The company began the voluntary recall on October 7, 2026. On October 26, the FDA classified it as a Class II recall.
That is the middle tier on the agency's scale, covering products that may cause temporary or medically reversible health problems, with a low chance of serious harm.
Also read: A 24-year-old runner dies after collapsing near the marathon finish line: Here's what happened
The exact bottles the FDA flagged
Two lots are affected, both expiring May 31, 2027. The first is lot 12251163A, a 30-count bottle with NDC 33342-246-07 on the label, covering 3,528 bottles.
The second is lot 12251163B, a 90-count bottle with NDC 33342-246-10, covering 216 bottles.
The medication was distributed nationwide. If you take this three-drug combination, look at the side of the bottle for the lot number and NDC code. If either matches, call your pharmacy. No injuries have been reported.
What a dissolution failure actually means
Dissolution testing measures how quickly a tablet breaks down and releases its active drug once it hits the stomach. If it dissolves too slowly, the medicine may not reach the bloodstream in the amount the prescription intends.
Also read: New melanoma shot built from your own tumor cuts recurrence by 42%
This is not a contamination problem. Nothing toxic was found in the pills. The concern is simply that the body may absorb less drug than the prescription calls for.
In this case, the olmesartan component of the tablet fell short of the required release standard, KTBS reported.
For people counting on the pill to lower their numbers, an under-releasing tablet can mean a temporary stretch of weaker control.
Weaker control is not a small thing. According to the CDC, nearly half of US adults, about 119.9 million people, have high blood pressure. Only about one in four has the condition under control.
Also read: The surprising reason cottage cheese may be one of the best bedtime snacks
What to do if your bottle matches
Do not stop taking the medication on your own. Suddenly halting a blood pressure drug can push readings sharply higher. It is never a safe move without a doctor's input.
Instead, keep taking your tablets and call your prescriber or pharmacist right away. They can arrange a replacement from an unaffected lot.
If you are not sure which lot you have, bring the bottle to the pharmacy counter. Pharmacists can match the lot and NDC against the recall list, especially for prescriptions that were repackaged into a different container.
Anyone who believes a recalled bottle may have affected their blood pressure control can also report the problem to the FDA through the agency's MedWatch reporting system.
Also read: Feeling stressed all the time? Here's what may be happening to your immune system
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.